featured
2021 Top Story in Lung Cancer: Changes in Paradigm for Potentially Curable NSCLC
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. Published online October 21, 2021. doi:10.1001/jamaoncol.2021.4932
- Update Estimates of NSCLC in the US. Published November 9, 2021. Accessed November 17, 2021.
- Saw SPL, Ong BH, Chua KLM, Takano A, Tan DSW. Revisiting neoadjuvant therapy in non-small-cell lung cancer. Lancet Oncol. 2021;22(11):e501-e516.
- Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021;22(6):824-835.
- Faivre-Finn C, Vicente D, Kurata T, et al. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021;16(5):860-867.
- Li N, Wang B-X, Li J, et al. Perioperative Circulating Tumor DNA as a Potential Prognostic Marker for Operable Stage I to IIIA Non–Small Cell Lung Cancer. Cancer. Published online October 18, 2021. doi:10.1002/cncr.33985